Seeking Alpha

Jazz rises following $1B deal for Gentium

  • Shares of Jazz Pharmaceuticals (JAZZ) are 7% higher in thin premarket trading on the heels of the company's Gentium (GENT) acquisition.
  • The deal gives the company Defitelio — the sVOD treatment that also has an Orphan designation in the EU for GvHD — which JAZZ says "is highly complementary to [the company's] experience in and focus on orphan diseases in the area of hematology/oncology."
  • JAZZ expects the deal to be immediately accretive. (PR)
Comments (1)
  • Gentium Bd of Directors may have helped themselves, but ignored shareholders. You've got to be kidding...$57 per share? We were at $55 already. Congressional investigation is due.
    20 Dec 2013, 12:13 PM Reply Like
DJIA (DIA) S&P 500 (SPY)